Olszewski, A., Avigdor, A., Babu, S., Levi, I., Eradat, H., Abadi, U., … Horowitz, N. (2021). Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 21, pp. S395–S396).

Olszewski, Adam, Abraham Avigdor, Sunil Babu, Itai Levi, Herbert Eradat, Uri Abadi, Houston Holmes, et al. “Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21:S395–96, 2021.

Olszewski A, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, et al. Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021. p. S395–6.

Olszewski, Adam, et al. “Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 21, 2021, pp. S395–96.

Olszewski A, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, Holmes H, McKinney M, Woszczyk D, Giannopoulos K, Jurczak W, McCord R, Xie Y, Zhou M, Qayum N, O’Hear C, Sellam G, Horowitz N. Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021. p. S395–S396.